Anti-PD-1 ICIs have achieved higher therapeutic responses than standard-of-care chemotherapy in patients with advanced NSCLC, both in the second-line [17–19] and first-line [20] setting. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.